Research is being conducted on targeted therapy approaches for triple negative breast cancer, with a focus on the epithelial-mesenchymal transition. Studies are exploring various aspects, including molecular signatures, therapeutic targets, and treatment resistance mechanisms. Investigators are also investigating potential therapeutic innovations, such as molecular targeting and monoclonal antibody strategies, to improve treatment outcomes for this type of cancer.